Answers are grounded in this paper and cite their sources.
Demonstrates enhanced cancer cell detection and navigation using a novel fluorescent probe, indicating improved surgical outcomes.
This study addresses the critical clinical challenge of precise identification and treatment of cancer cells by proposing a novel targeting strategy based on differences in plasma membrane viscosity, and accordingly developing a multicharged foldable fluorescent probe, CSP-BP-CSP. Through rational structural design featuring a rigid bipyridine bridge and four cationic pyridinium units, the probe achieves high-affinity membrane anchoring with minimal cellular internalization, thereby significantly improving the signal-to-noise ratio and enabling long-term tracking. CSP-BP-CSP sensitively responds to viscosity variations between cancerous and normal cell membranes, allowing high-contrast specific cancer cell recognition and prolonged membrane labeling. Upon membrane damage, the probe translocates into the nucleus, enabling real-time monitoring of apoptosis. In animal models, CSP-BP-CSP exhibits sustained tumor-specific accumulation and has been successfully applied to fluorescence-guided precise tumor resection. Furthermore, the probe was employed to evaluate the antitumor efficacy of deuterium-enriched water, demonstrating its potential for theranostic integration. This work not only provides a new design strategy for membrane-anchored probes but also offers a versatile molecular platform for precise cancer diagnosis, intraoperative navigation, and treatment monitoring.
No takes yet. Share an insight, caveat, or question.
Zuo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: